Table 3.
Co-occurrence of TTIs serologic markers among the MI positive cases
| Variable | Total of MI | Co-occurrence: % (N) | P value | |||||
|---|---|---|---|---|---|---|---|---|
| anti-HIV/HBVsAg | anti-HIV/anti-HCV | anti-HIV/anti-TP | HBVsAg/anti-HCV | HBVsAg/anti-TP | anti-HCV/anti-TP | |||
| Overall | 65 | 23.07 (15) | 16.92 (11) | 27.70 (18) | 4.61 (3) | 20 (13) | 7.70 (5) | 0.002a |
| Age | ||||||||
| 18–27 years | 25 | 24 (6) | 0 (0) | 36 (9) | 4 (1) | 28 (7) | 8 (2) | 0.001 |
| 28–37 years | 21 | 33.33 (7) | 19.05 (4) | 28.57 (6) | 0 (0) | 14.29 (3) | 4.76 (1) | 0.014 |
| 38–47 years | 19 | 10.52 (2) | 36.84 (7) | 15.80 (3) | 10.52 (2) | 15.80 (3) | 10.52 (2) | 0.316 |
| P value | 0.567 | 0.139 | 0.008 | 0.122 | 0.679 | 0.196 | 1.000 | |
| Residence | ||||||||
| Al Douiem | 12 | 25 (3) | 8.33 (1) | 25 (3) | 0 (0) | 41.67 (5) | 0 (0) | 0.025 |
| Kosti | 27 | 29.63 (8) | 14.82 (4) | 22.22 (6) | 11.11 (3) | 14.82 (4) | 7.40 (2) | 0.320 |
| Rabak | 26 | 15.38 (4) | 23.08 (6) | 34.62 (9) | 0 (0) | 15.38 (4) | 11.54 (3) | 0.017 |
| P value | 0.006 | 0.208 | 0.100 | 0.122 | 0.036 | 1.000 | 0.251 | |
MI Multiple infections, N Number, HIV Human immunodeficiency virus, HBVsAg Hepatitis B virus surface antigen, HCV Hepatitis C virus, TP T. palladium
Pearson Chi squareda and Fishers Exact test have involved in the Statistical analysis